These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 18001616)
61. Statins for high-risk patients without heart disease or high cholesterol. Med Lett Drugs Ther; 2006 Jan; 48(1225):1-3. PubMed ID: 16374400 [No Abstract] [Full Text] [Related]
62. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Davidson MH; Rooney MW; Drucker J; Eugene Griffin H; Oosman S; Beckert M; Clin Ther; 2009 Dec; 31(12):2824-38. PubMed ID: 20110022 [TBL] [Abstract][Full Text] [Related]
63. Economic evaluation of atorvastatin for prevention of recurrent stroke based on the SPARCL trial. Kongnakorn T; Ward A; Roberts CS; O'Brien JA; Proskorovsky I; Caro JJ Value Health; 2009 Sep; 12(6):880-7. PubMed ID: 19490555 [TBL] [Abstract][Full Text] [Related]
64. Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Sever PS; Poulter NR; Dahlöf B; Wedel H; Am J Cardiol; 2005 Sep; 96(5A):39F-44F. PubMed ID: 16126022 [TBL] [Abstract][Full Text] [Related]
65. Statins for the prevention of first or recurrent stroke. Athyros VG; Kakafika AI; Tziomalos K; Papageorgiou AA; Karagiannis A Curr Vasc Pharmacol; 2008 Apr; 6(2):124-33. PubMed ID: 18393914 [TBL] [Abstract][Full Text] [Related]
68. Atorvastatin Reduces First and Subsequent Vascular Events Across Vascular Territories: The SPARCL Trial. Szarek M; Amarenco P; Callahan A; DeMicco D; Fayyad R; Goldstein LB; Laskey R; Sillesen H; Welch KM; J Am Coll Cardiol; 2020 May; 75(17):2110-2118. PubMed ID: 32194196 [TBL] [Abstract][Full Text] [Related]
69. Atorvastatin for prevention of atrial fibrillation recurrence following pulmonary vein isolation: a double-blind, placebo-controlled, randomized trial. Suleiman M; Koestler C; Lerman A; Lopez-Jimenez F; Herges R; Hodge D; Bradley D; Cha YM; Brady PA; Munger TM; Asirvatham SJ; Packer DL; Friedman PA Heart Rhythm; 2012 Feb; 9(2):172-8. PubMed ID: 21920481 [TBL] [Abstract][Full Text] [Related]
70. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Waters DD; Schwartz GG; Olsson AG; Zeiher A; Oliver MF; Ganz P; Ezekowitz M; Chaitman BR; Leslie SJ; Stern T; Circulation; 2002 Sep; 106(13):1690-5. PubMed ID: 12270864 [TBL] [Abstract][Full Text] [Related]
71. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Malhotra HS; Goa KL Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468 [TBL] [Abstract][Full Text] [Related]
72. The case for early statin therapy in acute coronary syndromes. Arntz HR Cardiol Rev; 2002; 10(2):91-6. PubMed ID: 11895575 [TBL] [Abstract][Full Text] [Related]
73. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. Schwartz GG; Olsson AG; Ezekowitz MD; Ganz P; Oliver MF; Waters D; Zeiher A; Chaitman BR; Leslie S; Stern T; JAMA; 2001 Apr; 285(13):1711-8. PubMed ID: 11277825 [TBL] [Abstract][Full Text] [Related]
74. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin therapy: a large database analysis of managed care plans in the United States. Foody JM; Joyce AT; Rudolph AE; Liu LZ; Benner JS Clin Ther; 2008 Jan; 30(1):195-205. PubMed ID: 18343257 [TBL] [Abstract][Full Text] [Related]
75. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. Waters DD; Ho JE; Boekholdt SM; DeMicco DA; Kastelein JJ; Messig M; Breazna A; Pedersen TR J Am Coll Cardiol; 2013 Jan; 61(2):148-52. PubMed ID: 23219296 [TBL] [Abstract][Full Text] [Related]
76. Managing dyslipidemia in the high-risk patient. Stein EA Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720 [TBL] [Abstract][Full Text] [Related]
77. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Schwartz GG; Olsson AG; Szarek M; Sasiela WJ Diabetes Care; 2005 Oct; 28(10):2508-13. PubMed ID: 16186288 [TBL] [Abstract][Full Text] [Related]
78. Statins and CVD prevention in the diabetic population: implications of the CARDS trial. Murad O; Palmer J; Sowers J; McFarlane SI Curr Diab Rep; 2005 Jun; 5(3):191-3. PubMed ID: 15929865 [No Abstract] [Full Text] [Related]
79. Statin therapy after stroke or transient ischemic attack. Elkind MS N Engl J Med; 2006 Nov; 355(22):2369; author reply 2370-1. PubMed ID: 17139774 [No Abstract] [Full Text] [Related]
80. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. Pedersen TR; Faergeman O; Kastelein JJ; Olsson AG; Tikkanen MJ; Holme I; Larsen ML; Bendiksen FS; Lindahl C; Szarek M; Tsai J; JAMA; 2005 Nov; 294(19):2437-45. PubMed ID: 16287954 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]